# EDGAR Filing Document

**Accession Number:** 0001137360
**File Stem:** 0001410368-26-020317
**Filing Date:** 2026-2
**Character Count:** 16571
**Document Hash:** f8e487f73ef5681a19451d7720c4da3c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001410368-26-020317.hdr.sgml**: 20260227

**ACCESSION NUMBER**: 0001410368-26-020317

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20251231

**FILED AS OF DATE**: 20260227

**DATE AS OF CHANGE**: 20260227

**PERIOD START**: 20260930

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** VanEck ETF Trust
- **CENTRAL INDEX KEY:** 0001137360

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-10325
- **FILM NUMBER:** 26694356

**BUSINESS ADDRESS:**
- **STREET 1:** 666 THIRD AVENUE, 9TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
- **BUSINESS PHONE:** 212-293-2000

**MAIL ADDRESS:**
- **STREET 1:** 666 THIRD AVENUE, 9TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VanEck Vectors ETF Trust
- **DATE OF NAME CHANGE:** 20160427

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MARKET VECTORS ETF TRUST
- **DATE OF NAME CHANGE:** 20070312

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MARKET VECTORS TRUST
- **DATE OF NAME CHANGE:** 20050516

## Series and Classes Contracts Data

### VanEck Pharmaceutical ETF (Series ID: S000034409)

| Class ID   | Class Name                | Ticker Symbol   |
|:---|:---|:---|
| C000105867 | VanEck Pharmaceutical ETF | PPH             |

## Nport-Ex

VANECK

PHARMACEUTICAL

ETF

SCHEDULE

OF

INVESTMENTS

December

31,

2025

(unaudited)

#### FootnoteRuleAboveBlank

#### Footnotes:
\*

See

Schedule

of

Investments

for

geographic

sectors.

#### Number

#### of

#### Shares

#### Value

#### COMMON

#### STOCKS:

#### 100.0%

#### Denmark

#### :

#### 6.5%
Novo

Nordisk

A/S

(ADR)

1,645,149

$

83,705,181

Underline

#### France

#### :

#### 4.4%
Sanofi

SA

(ADR)

1,163,125

56,365,038

Underline

#### Israel

#### :

#### 2.6%
Teva

Pharmaceutical

Industries

Ltd.

(ADR) \*

1,082,983

33,799,899

Underline

#### Japan

#### :

#### 2.6%
Takeda

Pharmaceutical

Co.

Ltd.

(ADR) †

2,150,787

33,530,769

Underline

#### Switzerland

#### :

#### 10.0%
Novartis

AG

(ADR) †

945,379

130,339,403

Underline

#### United

#### Kingdom

#### :

#### 11.7%
AstraZeneca

PLC

(ADR)

613,411

56,390,873

GSK

PLC

(ADR) †

1,159,527

56,863,204

Haleon

PLC

(ADR) †

3,851,123

38,934,854

152,188,931

#### United

#### States

#### :

#### 62.2%
AbbVie,

Inc.

249,283

56,958,673

Axsome

Therapeutics,

Inc. \*

35,077

6,406,463

Bausch

Health

Cos,

Inc. \*

†

206,438

1,434,744

Bristol-Myers

Squibb

Co.

1,096,123

59,124,875

Cencora,

Inc.

152,334

51,450,809

Corcept

Therapeutics,

Inc. \*

63,779

2,219,509

#### Number

#### of

#### Shares

#### Value

#### United

#### States
(continued)

Elanco

Animal

Health,

Inc. \*

†

246,957

$

5,588,637

Eli

Lilly

&

Co.

251,075

269,825,281

Jazz

Pharmaceuticals

PLC \*

48,327

8,215,590

Johnson

&

Johnson

271,783

56,245,492

McKesson

Corp.

69,027

56,622,158

Merck

&

Co.,

Inc.

1,097,404

115,512,745

Organon

&

Co.

196,406

1,408,231

Perrigo

Co.

PLC †

79,334

1,104,329

Pfizer,

Inc.

2,419,290

60,240,321

Viatris,

Inc.

778,514

9,692,499

Zoetis,

Inc.

359,204

45,195,047

807,245,403

#### Total

#### Common

#### Stocks
(Cost:

$1,284,120,445)

1,297,174,624

#### SHORT-TERM

#### INVESTMENT

#### HELD

#### AS

#### COLLATERAL

#### FOR

#### SECURITIES

#### ON

#### LOAN:

#### 5.5%

#### Money

#### Market

#### Fund:

#### 5.5%
(Cost:

$71,830,886)

State

Street

Navigator

Securities

Lending

Government

Money

Market

Portfolio

3.80%(a)

71,830,886

71,830,886

#### Total

#### Investments:

#### 105.5%
(Cost:

$1,355,951,331)

1,369,005,510

#### Liabilities

#### in

#### excess

#### of

#### other

#### assets:

#### (5.5)%
(70,914,851)

#### NET

#### ASSETS:

#### 100.0%
$

1,298,090,659

#### Definitions:
ADR

American

Depositary

Receipt

\*

Non-income

producing

†

Security

fully

or

partially

on

loan.

Total

market

value

of

securities

on

loan

is

$176,618,036.

(a) Rate

shown

is

the

7-day

yield

as

of

12/31/25.

The

summary

of

inputs

used

to

value

the

Fund's

investments

as

of

December

31,

2025

is

as

follows:

#### Level

#### 1

#### Quoted

#### Prices

#### Level

#### 2

#### Significant

#### Observable

#### Inputs

#### Level

#### 3

#### Significant

#### Unobservable

#### Inputs

#### Value
Common

Stocks

\*

$

1,297,174,624

$

—

$

—

$

1,297,174,624

Money

Market

Fund

71,830,886

—

—

71,830,886

#### Total

#### Investments
$

1,369,005,510

$

—

$

—

$

1,369,005,510

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** VanEck ETF Trust

- **b. Investment Company Act file number:** 811-10325

- **c. CIK number of Registrant:** 0001137360

- **d. LEI of Registrant:** 549300ZLFKNTXC51ZN76

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** 666 THIRD AVENUE, 9TH FLOOR

  - **City:** NEW YORK

  - **State:** NY

  - **Foreign country:** US

  - **Zip / Postal Code:** 10017

  - **Telephone number:** 212-293-2000

**Item A.2. Information about the Series.**

- **a. Name of Series:** VanEck Pharmaceutical ETF

- **b. EDGAR series identifier (if any):** S000034409

- **c. LEI of Series:** 5493008SDOYUHMC8LF44

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2026-09-30

- **b. Date as of which information is reported:** 2025-12-31

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $1349552706.68

**Total Liabilities:** $72087296.78

**Net Assets:** $1277465409.90

**Monthly Return Information**

| Class               | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID C000105867 | 2.84%                | 10.84%               | 0.86%                |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $14141456.81             | $-6974857.87                               |
| Month 2  | $9851123.05              | $103234279.56                              |
| Month 3  | $23113042.85             | $-15120952.47                              |

### Schedule of Portfolio Investments

| Name                               | Title                                                                       | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| AbbVie Inc                         | AbbVie Inc                                                                  | CUSIP: 00287Y109<br>LEI: FR5LCKFTG8054YNNRU85 | Long             | EC               | CORP              | US        |    245319 | NS      | $56052938.31  | 4.39%             |  |  |  | No            |                  1 | On Loan: No      |
| Cencora Inc                        | Cencora Inc                                                                 | CUSIP: 03073E105<br>LEI: AI8GXW8LG5WK7E9UD086 | Long             | EC               | CORP              | US        |    149910 | NS      | $50632102.50  | 3.96%             |  |  |  | No            |                  1 | On Loan: No      |
| AstraZeneca PLC                    | AstraZeneca PLC                                                             | CUSIP: 046353108<br>LEI: PY6ZZQWO2IZFZC3IOL08 | Long             | EC               | CORP              | GB        |    603659 | NS      | $55494371.87  | 4.34%             |  |  |  | No            |                  1 | On Loan: No      |
| Axsome Therapeutics Inc            | Axsome Therapeutics Inc                                                     | CUSIP: 05464T104<br>LEI: 549300EXGR0XLRJEIB95 | Long             | EC               | CORP              | US        |     34521 | NS      | $6304915.44   | 0.49%             |  |  |  | No            |                  1 | On Loan: No      |
| Bausch Health Cos Inc              | Bausch Health Cos Inc                                                       | CUSIP: 071734107<br>LEI: B3BS7ACMDUWISF18KY76 | Long             | EC               | CORP              | CA        |    203154 | NS      | $1411920.30   | 0.11%             |  |  |  | No            |                  1 | On Loan: —       |
| Bristol-Myers Squibb Co            | Bristol-Myers Squibb Co                                                     | CUSIP: 110122108<br>LEI: HLYYNH7UQUORYSJQCN42 | Long             | EC               | CORP              | US        |   1078695 | NS      | $58184808.30  | 4.55%             |  |  |  | No            |                  1 | On Loan: No      |
| Corcept Therapeutics Inc           | Corcept Therapeutics Inc                                                    | CUSIP: 218352102<br>LEI: 529900EO9LUTFMZ7FF90 | Long             | EC               | CORP              | US        |     62763 | NS      | $2184152.40   | 0.17%             |  |  |  | No            |                  1 | On Loan: No      |
| Elanco Animal Health Inc           | Elanco Animal Health Inc                                                    | CUSIP: 28414H103<br>LEI: 549300SHPNDCE059M934 | Long             | EC               | CORP              | US        |    243029 | NS      | $5499746.27   | 0.43%             |  |  |  | No            |                  1 | On Loan: —       |
| GSK PLC                            | GSK PLC                                                                     | CUSIP: 37733W204<br>LEI: 5493000HZTVUYLO1D793 | Long             | EC               | CORP              | GB        |   1141091 | NS      | $55959102.64  | 4.38%             |  |  |  | No            |                  1 | On Loan: —       |
| Haleon PLC                         | Haleon PLC                                                                  | CUSIP: 405552100<br>LEI: 549300PSB3WWEODCUP19 | Long             | EC               | CORP              | GB        |   3789895 | NS      | $38315838.45  | 3.00%             |  |  |  | No            |                  1 | On Loan: —       |
| Johnson & Johnson                  | Johnson & Johnson                                                           | CUSIP: 478160104<br>LEI: 549300G0CFPGEF6X2043 | Long             | EC               | CORP              | US        |    267463 | NS      | $55351467.85  | 4.33%             |  |  |  | No            |                  1 | On Loan: No      |
| Eli Lilly & Co                     | Eli Lilly & Co                                                              | CUSIP: 532457108<br>LEI: FRDRIPF3EKNDJ2CQJL29 | Long             | EC               | CORP              | US        |    247083 | NS      | $265535158.44 | 20.79%            |  |  |  | No            |                  1 | On Loan: No      |
| McKesson Corp                      | McKesson Corp                                                               | CUSIP: 58155Q103<br>LEI: 549300WZWOM80UCFSF54 | Long             | EC               | CORP              | US        |     67931 | NS      | $55723119.99  | 4.36%             |  |  |  | No            |                  1 | On Loan: No      |
| Merck & Co Inc                     | Merck & Co Inc                                                              | CUSIP: 58933Y105<br>LEI: 4YV9Y5M8S0BRK1RP0397 | Long             | EC               | CORP              | US        |   1079956 | NS      | $113676168.56 | 8.90%             |  |  |  | No            |                  1 | On Loan: No      |
| Novartis AG                        | Novartis AG                                                                 | CUSIP: 66987V109<br>LEI: 5493007HIVTX6SY6XD66 | Long             | EC               | CORP              | CH        |    930347 | NS      | $128266940.89 | 10.04%            |  |  |  | No            |                  1 | On Loan: —       |
| Novo Nordisk A/S                   | Novo Nordisk A/S                                                            | CUSIP: 670100205<br>LEI: 549300DAQ1CVT6CXN342 | Long             | EC               | CORP              | DK        |   1618993 | NS      | $82374363.84  | 6.45%             |  |  |  | No            |                  1 | On Loan: No      |
| Organon & Co                       | Organon & Co                                                                | CUSIP: 68622V106<br>LEI: 549300AMCKY57OK2CO56 | Long             | EC               | CORP              | US        |    193282 | NS      | $1385831.94   | 0.11%             |  |  |  | No            |                  1 | On Loan: No      |
| Pfizer Inc                         | Pfizer Inc                                                                  | CUSIP: 717081103<br>LEI: 765LHXWGK1KXCLTFYQ30 | Long             | EC               | CORP              | US        |   2380826 | NS      | $59282567.40  | 4.64%             |  |  |  | No            |                  1 | On Loan: No      |
| Sanofi SA                          | Sanofi SA                                                                   | CUSIP: 80105N105<br>LEI: 549300E9PC51EN656011 | Long             | EC               | CORP              | FR        |   1144633 | NS      | $55468915.18  | 4.34%             |  |  |  | No            |                  1 | On Loan: No      |
| Takeda Pharmaceutical Co Ltd       | Takeda Pharmaceutical Co Ltd                                                | CUSIP: 874060205<br>LEI: 549300ZLMVP4X0OGR454 | Long             | EC               | CORP              | JP        |   2116591 | NS      | $32997653.69  | 2.58%             |  |  |  | No            |                  1 | On Loan: —       |
| Teva Pharmaceutical Industries Ltd | Teva Pharmaceutical Industries Ltd                                          | CUSIP: 881624209<br>LEI: 549300BAFGM4RC74ZJ94 | Long             | EC               | CORP              | IL        |   1065763 | NS      | $33262463.23  | 2.60%             |  |  |  | No            |                  1 | On Loan: No      |
| Viatris Inc                        | Viatris Inc                                                                 | CUSIP: 92556V106<br>LEI: 254900ZZTSW7NL773X71 | Long             | EC               | CORP              | US        |    766138 | NS      | $9538418.10   | 0.75%             |  |  |  | No            |                  1 | On Loan: No      |
| Zoetis Inc                         | Zoetis Inc                                                                  | CUSIP: 98978V103<br>LEI: 549300HD9Q1LOC9KLJ48 | Long             | EC               | CORP              | US        |    353492 | NS      | $44476363.44  | 3.48%             |  |  |  | No            |                  1 | On Loan: No      |
| State Street Global Advisors       | State Street Navigator Securities Lending Government Money Market Portfolio | CUSIP: 857509301<br>LEI: 5493008BJIBKQ5KTIF74 | Long             | STIV             | RF                | US        |  71676808 | NS      | $71676807.75  | 5.61%             |  |  |  | No            |                  1 | On Loan: No      |
| Jazz Pharmaceuticals PLC           | Jazz Pharmaceuticals PLC                                                    | CUSIP: 000000000<br>LEI: 635400GAUMJCLEZRRV50 | Long             | EC               | CORP              | IE        |     47559 | NS      | $8085030.00   | 0.63%             |  |  |  | No            |                  1 | On Loan: No      |
| Perrigo Co PLC                     | Perrigo Co PLC                                                              | CUSIP: 000000000<br>LEI: 549300IFOQS6R1QLY196 | Long             | EC               | CORP              | IE        |     78074 | NS      | $1086790.08   | 0.09%             |  |  |  | No            |                  1 | On Loan: —       |

### Signature

**Date Signed:** 2026-01-30

**Name of Applicant:** VanEck ETF Trust

**Signature:** James Parker

**Name of Signer:** James Parker

**Title:** Assistant Treasurer